GlassScriptPhysician profile
Julie P Balk
NPI 1932239720
$1,222.76
in general payments reported to CMS, 2019-2025
24 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.55 · 2022: $67.57 · 2023: $311 · 2024: $328 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.64 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $131.13 | 2023-2025 | Enhertu, Imfinzi, Calquence |
| Seagen INC. | $116.68 | 2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $112.85 | 2023-2025 | Eliquis, Opdivo |
| Gilead Sciences, INC. | $111.93 | 2021-2024 | |
| Eisai INC. | $100.63 | 2022-2025 | |
| Exeltis, USA INC. | $96.75 | 2024-2025 | Slynd, Twirla |
| Abbvie INC. | $68.82 | 2023-2024 | |
| Glaxosmithkline, LLC. | $63.59 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $54.65 | 2024-2025 | Enhertu |
| Emd Serono, INC. | $49.63 | 2022-2025 | |
| Tempus Ai, INC | $38.87 | 2025 | Xt Cdx |
| Azurity Pharmaceuticals, INC. | $37.95 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $28.09 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Pfizer INC. | $27.49 | 2024-2025 | |
| Incyte Corporation | $25.69 | 2025 | Jakafi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $20.84 | 2025 | Monoferric |
| Recordati_rare_diseases_inc. | $19.73 | 2023 | Sylvant |
| Celgene Corporation | $19.64 | 2025 | Reblozyl |
| Stemline Therapeutics INC. | $18.47 | 2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.74 | 2025 | |
| Organon LLC | $17.08 | 2022 | |
| Janssen Biotech, INC. | $15.88 | 2025 | Balversa, Erleada |
| Astellas Pharma US INC | $14.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.03 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Balk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.